

caspase-7 (11.1.56): sc-81655

BACKGROUND

A unique family of Cysteine proteases has been described that differs in sequence, structure and substrate specificity from any previously described protease family. This family, Ced-3/caspase-1, is comprised of caspase-1, caspase-2, caspase-3, caspase-4, caspase-6, caspase-7 (also designated Mch3, ICE-LAP3 or CMH-1), caspase-9 and caspase-10. Ced-3/caspase-1 family members function as key components of the apoptotic machinery and act to destroy specific target proteins which are critical to cellular longevity. Poly(ADP-ribose) polymerase plays an integral role in surveying for DNA mutations and double strand breaks. Caspase-3, caspase-7 and caspase-9, but not caspase-1, have been shown to cleave the nuclear protein PARP into an apoptotic fragment. Caspase-6, but not caspase-3, has been shown to cleave the nuclear lamins which are critical to maintaining the integrity of the nuclear envelope and cellular morphology. Caspase-10 has been shown to activate caspase-3 and caspase-7 in response to apoptotic stimuli.

REFERENCES

1. Tiso, N., et al. 1996. Chromosomal localization of the human genes, CPP32, MCH2, MCH3, and ICH1, involved in cellular apoptosis. *Biochem. Biophys. Res. Commun.* 225: 983-989.
2. Cohen, G.M. 1997. Caspases: the executioners of apoptosis. *Biochem. J.* 326: 1-16.
3. Chandler, J.M., et al. 1998. Different subcellular distribution of caspase-3 and caspase-7 following FAS-induced apoptosis in mouse liver. *J. Biol. Chem.* 273: 10815-10818.
4. Marcelli, M., et al. 1999. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. *Cancer Res.* 59: 382-390.
5. Germain, M., et al. 1999. Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. *J. Biol. Chem.* 274: 28379-28384.

CHROMOSOMAL LOCATION

Genetic locus: CASP7 (human) mapping to 10q25.3; Casp7 (mouse) mapping to 19 D2.

SOURCE

caspase-7 (11.1.56) is a mouse monoclonal antibody raised against full-length recombinant caspase-7 of human origin.

PRODUCT

Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

caspase-7 (11.1.56) is recommended for detection of caspase-7 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)].

Suitable for use as control antibody for caspase-7 siRNA (h): sc-29929, caspase-7 siRNA (m): sc-29928, caspase-7 shRNA Plasmid (h): sc-29929-SH, caspase-7 shRNA Plasmid (m): sc-29928-SH, caspase-7 shRNA (h) Lentiviral Particles: sc-29929-V and caspase-7 shRNA (m) Lentiviral Particles: sc-29928-V.

Molecular Weight of procaspase-7 splice variants: 28-38 kDa.

Molecular Weight of caspase-7 p20 subunit: 20 kDa.


Molecular Weight of caspase-7 p10 subunit: 10 kDa.

Positive Controls: Jurkat whole cell lysate: sc-2204, caspase-7 (h): 293 Lysate: sc-112228 or HeLa whole cell lysate: sc-2200.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml).

DATA



caspase-7 (11.1.56): sc-81655. Western blot analysis of procaspase-7 expression in non-transfected 293: sc-110760 (A), human caspase-7 transfected 293: sc-112228 (B) and HeLa (C) whole cell lysates.

SELECT PRODUCT CITATIONS

1. Chen, W.T., et al. 2017. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. *J. Ovarian Res.* 10: 1.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.